Searchable abstracts of presentations at key conferences in endocrinology

ea0014s10.4 | GH and prolactin at their targets | ECE2007

Development of human prolactin receptor antagonists

Goffin Vincent , Rouet Vincent , Jomain Jean-Baptiste , Tallet Estelle , Kayser Christine , Kelly Paul A.

Experimental, clinical and/or epidemiological evidence points to a role for prolactin (PRL) in the promotion of benign and malignant tumors of the breast and the prostate. However, therapies reducing PRL levels (dopamine agonists) are currently not considered for the treatment of these pathologies. Dopamine agonists only target PRL secretion from the pituitary, while recent observations suggest that the involvement of autocrine PRL is perhaps even more relevant than circulatin...

ea0070aep671 | Pituitary and Neuroendocrinology | ECE2020

To score or not to score? Is Ki-67 analysis worthwhile in pituitary neuroendocrine tumours?

Benjamin Loughrey Paul , Craig Stephanie , Herron Brian , Abdullahi Sidi Fatima , McQuaid Stephen , Kelly Paul , Humphries Matt , Parkes Eileen , McArt Darragh , Hunter Steven , Korbonits Marta , James Jacqueline

Pituitary neuroendocrine tumours (PitNETs) are heterogeneous and have limited biomarkers to predict their behaviour, thus making their prognostication difficult. Ki-67 is a protein expressed in active phases of the cell cycle and is one of the biomarkers utilized in routine assessment of PitNET tissue. Current European Society of Endocrinology recommendations advise that histopathological analysis of PitNETs should as a minimum include Ki-67 proliferation index and anterior pi...